Replies to post #186640 on Biotech Values

[DewDiligence]

BMY—Yervoy is now selling at an annualized rate of $1.5B, and Eliquis (co-marketed with PFE) is now selling at an annualized rate of $1.1B:

http://finance.yahoo.com/news/bristol-myers-squibb-reports-fourth-123000985.html

As noted in #msg-110284729, Eliquis has surpassed market-leader Xarelto in new-prescription share in the Us and Japan.

[jq1234]

Can't believe ARYX's tecarfarin is back:

Tecarfarin has been on this stage before. It failed a clinical trial in 2009 when it couldn’t beat warfarin—an anticoagulant drug that’s been around for decades—head to head. That led its original owner, ARYx Therapeutics, into a tailspin it never recovered from, closing down for good in 2011.

ARYx’s executives, however, didn’t give up. Founder Peter Milner took the drug over to a new company, Armetheon, in 2011. And the startup has found a new way to breathe life into tecarfarin by targeting a specific group of patients that don’t respond well to warfarin.

http://www.xconomy.com/san-francisco/2015/02/09/cardio-study-gives-life-to-armetheons-blood-thinning-drug/

[DewDiligence]

Eliquis now selling at a $1.75B annualized rate, +171% YoY. Pretty impressive uptake after such a slow start.